Fenofibrate Tablet Franchise in Ahmedabad

Fenofibrate 145mg Tablet in pharmaceutical manufacturing company in Mumbai

Fenofibrate 145mg Tablet in cardiac care pharma franchise in Pune

Fenofibrate 145mg Tablet in pharma suppliers in Delhi

Fenofibrate 145mg Tablet in pharma export companies in Kolkata
Fenofibrate 145mg Tablet in pharma franchise opportunities in Bengaluru

Home/Products /fenofibrate-145-mg-tablet

Fenoflick 145 Tablet

Composition : Fenofibrate (145mg) tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹185/-

Fenoflick 145 Tablet contains Fenofibrate 145mg, a lipid-lowering agent used for management of high cholesterol, elevated triglycerides, and mixed dyslipidemia. It helps reduce cardiovascular risk in patients with lipid disorders.

Fenofibrate works by activating peroxisome proliferator-activated receptor alpha (PPARα), which increases lipid metabolism, reduces triglycerides, and improves HDL cholesterol levels. This mechanism supports overall cardiovascular health.

This tablet is commonly prescribed for patients with hyperlipidemia, mixed dyslipidemia, or metabolic syndrome, providing effective lipid control and long-term prevention of cardiovascular events.

Fenoflick 145 Tablet is valued for its efficacy, clinical reliability, and high prescription demand, making it a trusted option in cardiac care. Its role in managing cholesterol and triglycerides supports heart health and enhances patient adherence in chronic therapy regimens.

Read More

About the Product

Fenoflick 145 Tablet contains Fenofibrate 145mg, a lipid-lowering agent used for management of high cholesterol, elevated triglycerides, and mixed dyslipidemia. It helps reduce cardiovascular risk in patients with lipid disorders.

Fenofibrate works by activating peroxisome proliferator-activated receptor alpha (PPARα), which increases lipid metabolism, reduces triglycerides, and improves HDL cholesterol levels. This mechanism supports overall cardiovascular health.

This tablet is commonly prescribed for patients with hyperlipidemia, mixed dyslipidemia, or metabolic syndrome, providing effective lipid control and long-term prevention of cardiovascular events.

Fenoflick 145 Tablet is valued for its efficacy, clinical reliability, and high prescription demand, making it a trusted option in cardiac care. Its role in managing cholesterol and triglycerides supports heart health and enhances patient adherence in chronic therapy regimens.

Common side effects may include gastrointestinal discomfort, nausea, abdominal pain, or mild headache. Rare but serious side effects include liver enzyme elevations, muscle pain or weakness (myopathy), and allergic reactions. Patients should report persistent or severe symptoms to their healthcare provider.

Fenoflick 145 Tablet is indicated for the treatment of hypertriglyceridemia, mixed dyslipidemia, and hypercholesterolemia, particularly in patients at risk of cardiovascular disease. It is used as part of a comprehensive treatment plan including diet, exercise, and lifestyle modifications.

Fenoflick 145 Tablet should be taken exactly as prescribed, preferably with meals. Liver function tests may be required periodically during treatment. Patients should avoid combining with other lipid-lowering medications without medical advice and maintain regular monitoring of kidney and liver function.

Store Fenoflick 145 Tablet in a cool, dry place away from direct sunlight and moisture. Keep out of reach of children and do not use after the expiry date mentioned on the packaging.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation